IMMX
Immix Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.97
+3.37%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$7.97
From 52W high−44.92%
Volume1.23M
Market cap$662.14M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$7.97
From 52W high
−44.92%
Volume
1.23M
Market cap
$662.14M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.7x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
+3.37%
YTD Return
+46.85%
SummaryUpdated Jun 1, 2026
Immix Biopharma, Inc. (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Los Angeles, California. The company went public in December 2021 and focuses on developing tissue-specific therapeutics for oncology and inflammatory diseases. Immix operates primarily in the United States and Australia, with its lead programs currently in various phases of clinical trials targeting cancer and inflammatory bowel diseases.
Similar companies
Latest newsMore news →
Immix Biopharma priced an underwritten registered offering of 11,363,637 common shares at $11.00 per share, expecting gross proceeds of $125 million and a close on or about September 30, 2026.36d agoImmix Biopharma announced an interim update showing an 89% complete response rate across all NEXICART-2 patients, with MRD-negativity indicating a potential to reach up to 98% complete response rate in relapsed/refractory AL amyloidosis.36d ago